Haemangiosarcoma

Verify with FDA CVM →

VeDDRA Code: 2072

198 adverse event reports referencing this reaction

198
Total Reports
126
Deaths
6360.0%
Death Rate

Species Most Affected

Dog 193
Cat 5

Breeds Most Affected

Retriever - Labrador 27
Retriever - Golden 25
Dog (unknown) 15
Crossbred Canine/dog 13
Shepherd Dog - German 13
Terrier - Bull - American Pit 10
Shepherd Dog - Australian 9
Beagle 5
Poodle - Standard 5
Domestic Shorthair 4

Associated Drugs

Oclacitinib Maleate 50
Milbemycin Oxime + Spinosad 31
Carprofen 19
Milbemycin Oxime + Praziquantel 14
Trilostane 11
Maropitant Citrate 10
Polysulfated Glycosaminoglycan 9
Cyclosporine 9
Gabapentin 8
Afoxolaner 8
Grapiprant 8
Fluralaner 13.64% 12-Week Chew 7
Cyclosporine A 6
Fluralaner Chew Tablets 6
Ivermectin + Pyrantel As Pamoate Salt 6
Anti-Il31 Mab Mcs Lot #1283563 6
Spinosad 5
Metronidazole 5
Firocoxib 227 Mg Chewable 4
Firocoxib 4

Data Summary

Metric Value
Total reports referencing reaction 198
Reports with fatal outcome 126
Case-fatality rate (reported events) 6360.0%
Species observed 2
Breeds observed 20
Drugs associated with reaction 20

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER); reaction term coded under VeDDRA 2072.

Haemangiosarcoma Reaction Insights

The FDA Center for Veterinary Medicine database currently lists 198 adverse event reports that reference Haemangiosarcoma as a reaction term, including 126 reports with a death outcome — a 6360.0% case-fatality figure calculated across only those events where this reaction was coded. The reaction is indexed in the openFDA system under VeDDRA code 2072, the standardized veterinary dictionary used to normalize clinical signs across submitters. Because reports are voluntary and often describe multiple concurrent signs per animal, the volume here reflects reporting intensity rather than true incidence in the broader pet population.

Haemangiosarcoma appears most frequently in reports for Dog (193 reports), Cat (5 reports) — with Dog dominating at 193 entries. Within those species, the breeds most often named alongside this reaction are Retriever - Labrador (27), Retriever - Golden (25), Dog (unknown) (15). These distributions are influenced both by underlying breed popularity and by how veterinarians and owners code a given clinical sign, so they should be interpreted as a reporting fingerprint rather than a pure susceptibility ranking.

The drugs most commonly co-reported with Haemangiosarcoma are Oclacitinib Maleate (50 reports), Milbemycin Oxime + Spinosad (31 reports), Carprofen (19 reports), Milbemycin Oxime + Praziquantel (14 reports), with Oclacitinib Maleate appearing alongside this reaction in 50 submissions. Co-reporting does not establish that any specific product caused the reaction — FDA CVM data captures temporal association only. The value of these aggregates is in flagging which therapeutic classes appear repeatedly alongside a given clinical sign, so owners and veterinarians can ask targeted questions about medications currently in use.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial